The Journal of clinical psychiatry
-
Letter Case Reports
Bipolar depression associated with fenfluramine and phentermine.
-
Multicenter Study Clinical Trial
A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.
This prospective 105-site study was conducted to determine the rate of seizures and other serious adverse experiences associated with the therapeutic use of the sustained-release formulation of bupropion (bupropion SR). ⋯ The therapeutic use of bupropion SR at total daily doses up to 300 mg/day in depressed patients without predisposition to seizures is associated with a seizure rate that is well within the range observed with other marketed antidepressants.